2018
Age of Data at the Time of Publication of Contemporary Clinical Trials
Welsh J, Lu Y, Dhruva SS, Bikdeli B, Desai NR, Benchetrit L, Zimmerman CO, Mu L, Ross JS, Krumholz HM. Age of Data at the Time of Publication of Contemporary Clinical Trials. JAMA Network Open 2018, 1: e181065-e181065. PMID: 30646100, PMCID: PMC6324269, DOI: 10.1001/jamanetworkopen.2018.1065.Peer-Reviewed Original ResearchConceptsClinical trialsFinal data collectionParticipant enrollmentInternal medicineMultivariable linear regression analysisFirst participant enrollmentPrimary end pointMultivariable regression analysisContemporary clinical trialsClinical trial dataJAMA Internal MedicineRegression analysisCross-sectional analysisTime of publicationMedian timeTrial characteristicsOutcome measuresMAIN OUTCOMENew England JournalClinical practiceLinear regression analysisTrial dataEnd pointTrial resultsTrialsAccurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population
Warner F, Dhruva SS, Ross JS, Dey P, Murugiah K, Krumholz HM. Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population. BMJ Open 2018, 8: e021685. PMID: 30037874, PMCID: PMC6059296, DOI: 10.1136/bmjopen-2018-021685.Peer-Reviewed Original ResearchConceptsSystolic Blood Pressure Intervention TrialFramingham risk scoreCardiovascular riskRisk scoreStudy populationStudy participantsNon-diabetic adultsTotal study populationHigh-risk populationClinical trial dataClinical trial sitesTrial populationIntervention trialsRisk populationsNew England JournalIndependent investigatorsTrial dataSecondary analysisSPRINT trialSPRINT dataTrialsRiskScoresParticipantsPopulation
2016
Availability of Clinical Trial Data From Industry‐Sponsored Cardiovascular Trials
Murugiah K, Ritchie JD, Desai NR, Ross JS, Krumholz HM. Availability of Clinical Trial Data From Industry‐Sponsored Cardiovascular Trials. Journal Of The American Heart Association 2016, 5: e003307. PMID: 27098969, PMCID: PMC4859296, DOI: 10.1161/jaha.116.003307.Peer-Reviewed Original ResearchConceptsIndividual participant-level dataLarge cardiovascular trialsCardiovascular trialsParticipant-level dataClinical trial dataPharmaceutical companiesMajor pharmaceutical companiesIndustry-sponsored clinical trialsInterventional trialsAvailable trialsClinical trialsTrial dataTrialsPatientsSpecific reasons
2013
Implications of clinical trial data sharing for medical writers
Ross J, Krumholz H. Implications of clinical trial data sharing for medical writers. Medical Writing 2013, 22: 45-48. DOI: 10.1179/2047480612z.00000000085.Commentaries, Editorials and Letters
2012
Sharing of clinical trial data among trialists: a cross sectional survey
Rathi V, Dzara K, Gross CP, Hrynaszkiewicz I, Joffe S, Krumholz HM, Strait KM, Ross JS. Sharing of clinical trial data among trialists: a cross sectional survey. The BMJ 2012, 345: e7570. PMID: 23169870, PMCID: PMC3502744, DOI: 10.1136/bmj.e7570.Peer-Reviewed Original ResearchConceptsClinical trial dataTrial dataGeneral medical journalsHigh-impact general medical journalsCross-sectional surveyDe-identified dataMedical journalsClinical trialsTrial fundersClinical trialistsSectional surveyTrialistsTrialsInvestigatorsExperiences of sharingPrevalence of dataPotential respondentsHigh impact factorAppropriate data usePrevalenceRespondents
2009
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance. JAMA Internal Medicine 2009, 169: 1976-1985. PMID: 19933959, PMCID: PMC2830805, DOI: 10.1001/archinternmed.2009.394.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsCardiovascular SystemCyclooxygenase 2 InhibitorsDrug IndustryHumansIncidenceLactonesMyocardial InfarctionRandomized Controlled Trials as TopicRisk AssessmentSafety-Based Drug WithdrawalsSulfonesTime FactorsUnited StatesUnited States Food and Drug AdministrationConceptsPlacebo-controlled trialVoluntary market withdrawalAdverse eventsCardiovascular riskThromboembolic adverse eventsMain outcome measurementsClinical trial dataRofecoxib groupOutcome measurementsTrial dataPlaceboTrial durationSafety surveillanceTrialsMarket withdrawalDeathRiskP-valueSurveillance effortsSubjectsWithdrawalRofecoxibYearsIncidenceDose
2003
Validity of a Simple ST-Elevation Acute Myocardial Infarction Risk Index
Rathore SS, Weinfurt KP, Gross CP, Krumholz HM. Validity of a Simple ST-Elevation Acute Myocardial Infarction Risk Index. Circulation 2003, 107: 811-816. PMID: 12591749, DOI: 10.1161/01.cir.0000049743.45748.02.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCalibrationCohort StudiesElectrocardiographyFemaleHumansInpatientsMaleMyocardial InfarctionMyocardial ReperfusionPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicReproducibility of ResultsRetrospective StudiesRiskRisk AssessmentSurvival AnalysisConceptsSimple risk indexCommunity-based cohortRCT populationMyocardial infarctionST-segment elevation myocardial infarctionST-elevation myocardial infarctionMyocardial Infarction (TIMI) risk indexRandomized clinical trial dataAcute reperfusion therapyPatients 65 yearsRisk stratification scoresElevation myocardial infarctionCommunity-based populationDistribution of patientsHigh-risk groupLow-risk groupRisk stratification indexClinical trial dataYears of ageRisk indexReperfusion therapyRisk score distributionPrognostic scoreMortality estimatesGeneral population